Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study

Berardino De Bari, Bradley Stish, Mark Wayne Ball, Yacob Habboush, Paul Sargos, Marco Krengli, Alberto Bossi, Armando Stabile, Claudio Sole Pesutic, Laëtitia Lestrade, Robert Jan Smeenk, Barbara Alicja Jereczek-Fossa, Thomas Zilli, Gilles Créhange, Filippo Alongi, Nicholas Zaorsky, Mahmut Ozsahin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Adult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients. Materials and Methods: This study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22-87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40). Curative radiotherapy (RT) was delivered in 32 patients, as radical (n = 5), neoadjuvant (n = 10), or postoperative treatment (n = 17). Eighteen patients received chemotherapy. None of the patients received hormonal therapy. Results: Median follow-up was 72 months (95%CI: 55-not reached). Five-year local control (LC), overall survival (OS), cancer-specific survival, disease-free survival, and metastases-free rates were 47%, 53%, 56%, 35%, and 35%, respectively. Notably, curative RT (neoadjuvant, adjuvant, or definitive) was associated with improved 5-year LC (55% vs. 31%, P = 0.02) and OS (59% vs. 46%, P = 0.1). Surgically treated patients presenting with a cT3-4 tumor (n = 31), who received RT (n = 24), had a significantly improved 5-year LC (68% vs, 33%, P = 0.004) and OS (65% vs. 21%, P < 0.001) rates compared to patients not receiving RT. cT4 patients demonstrated a significantly lower 5-year OS (43% vs. 61%, P = 0.006) and LC (29% vs. 69%, P < 0.001) rates. Histologic subtype was not associated with LC and OS, but patients with prostatic stromal sarcoma, rhabdomyosarcoma, or sarcomatoid carcinoma had worse 5-year LC compared to other types (47% vs. 55%) and OS (49% vs. 58%). Conclusion: Adult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS.

Original languageEnglish (US)
Pages (from-to)1160-1166
Number of pages7
JournalProstate
Volume77
Issue number10
DOIs
StatePublished - Jul 1 2017

Fingerprint

Sarcoma
Neoplasms
Survival
Radiotherapy
Adjuvant Radiotherapy
Rhabdomyosarcoma
Prostatectomy
Rare Diseases
Lymph Node Excision
Disease-Free Survival
Therapeutics
Survival Rate
Neoplasm Metastasis
Carcinoma
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

De Bari, B., Stish, B., Ball, M. W., Habboush, Y., Sargos, P., Krengli, M., ... Ozsahin, M. (2017). Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate, 77(10), 1160-1166. https://doi.org/10.1002/pros.23375
De Bari, Berardino ; Stish, Bradley ; Ball, Mark Wayne ; Habboush, Yacob ; Sargos, Paul ; Krengli, Marco ; Bossi, Alberto ; Stabile, Armando ; Sole Pesutic, Claudio ; Lestrade, Laëtitia ; Smeenk, Robert Jan ; Jereczek-Fossa, Barbara Alicja ; Zilli, Thomas ; Créhange, Gilles ; Alongi, Filippo ; Zaorsky, Nicholas ; Ozsahin, Mahmut. / Adult prostatic sarcoma : A contemporary multicenter Rare Cancer Network study. In: Prostate. 2017 ; Vol. 77, No. 10. pp. 1160-1166.
@article{bb0814ca0c6d4fca877229123a524d00,
title = "Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study",
abstract = "Introduction: Adult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients. Materials and Methods: This study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22-87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40). Curative radiotherapy (RT) was delivered in 32 patients, as radical (n = 5), neoadjuvant (n = 10), or postoperative treatment (n = 17). Eighteen patients received chemotherapy. None of the patients received hormonal therapy. Results: Median follow-up was 72 months (95{\%}CI: 55-not reached). Five-year local control (LC), overall survival (OS), cancer-specific survival, disease-free survival, and metastases-free rates were 47{\%}, 53{\%}, 56{\%}, 35{\%}, and 35{\%}, respectively. Notably, curative RT (neoadjuvant, adjuvant, or definitive) was associated with improved 5-year LC (55{\%} vs. 31{\%}, P = 0.02) and OS (59{\%} vs. 46{\%}, P = 0.1). Surgically treated patients presenting with a cT3-4 tumor (n = 31), who received RT (n = 24), had a significantly improved 5-year LC (68{\%} vs, 33{\%}, P = 0.004) and OS (65{\%} vs. 21{\%}, P < 0.001) rates compared to patients not receiving RT. cT4 patients demonstrated a significantly lower 5-year OS (43{\%} vs. 61{\%}, P = 0.006) and LC (29{\%} vs. 69{\%}, P < 0.001) rates. Histologic subtype was not associated with LC and OS, but patients with prostatic stromal sarcoma, rhabdomyosarcoma, or sarcomatoid carcinoma had worse 5-year LC compared to other types (47{\%} vs. 55{\%}) and OS (49{\%} vs. 58{\%}). Conclusion: Adult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS.",
author = "{De Bari}, Berardino and Bradley Stish and Ball, {Mark Wayne} and Yacob Habboush and Paul Sargos and Marco Krengli and Alberto Bossi and Armando Stabile and {Sole Pesutic}, Claudio and La{\"e}titia Lestrade and Smeenk, {Robert Jan} and Jereczek-Fossa, {Barbara Alicja} and Thomas Zilli and Gilles Cr{\'e}hange and Filippo Alongi and Nicholas Zaorsky and Mahmut Ozsahin",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/pros.23375",
language = "English (US)",
volume = "77",
pages = "1160--1166",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "10",

}

De Bari, B, Stish, B, Ball, MW, Habboush, Y, Sargos, P, Krengli, M, Bossi, A, Stabile, A, Sole Pesutic, C, Lestrade, L, Smeenk, RJ, Jereczek-Fossa, BA, Zilli, T, Créhange, G, Alongi, F, Zaorsky, N & Ozsahin, M 2017, 'Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study', Prostate, vol. 77, no. 10, pp. 1160-1166. https://doi.org/10.1002/pros.23375

Adult prostatic sarcoma : A contemporary multicenter Rare Cancer Network study. / De Bari, Berardino; Stish, Bradley; Ball, Mark Wayne; Habboush, Yacob; Sargos, Paul; Krengli, Marco; Bossi, Alberto; Stabile, Armando; Sole Pesutic, Claudio; Lestrade, Laëtitia; Smeenk, Robert Jan; Jereczek-Fossa, Barbara Alicja; Zilli, Thomas; Créhange, Gilles; Alongi, Filippo; Zaorsky, Nicholas; Ozsahin, Mahmut.

In: Prostate, Vol. 77, No. 10, 01.07.2017, p. 1160-1166.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adult prostatic sarcoma

T2 - A contemporary multicenter Rare Cancer Network study

AU - De Bari, Berardino

AU - Stish, Bradley

AU - Ball, Mark Wayne

AU - Habboush, Yacob

AU - Sargos, Paul

AU - Krengli, Marco

AU - Bossi, Alberto

AU - Stabile, Armando

AU - Sole Pesutic, Claudio

AU - Lestrade, Laëtitia

AU - Smeenk, Robert Jan

AU - Jereczek-Fossa, Barbara Alicja

AU - Zilli, Thomas

AU - Créhange, Gilles

AU - Alongi, Filippo

AU - Zaorsky, Nicholas

AU - Ozsahin, Mahmut

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Introduction: Adult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients. Materials and Methods: This study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22-87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40). Curative radiotherapy (RT) was delivered in 32 patients, as radical (n = 5), neoadjuvant (n = 10), or postoperative treatment (n = 17). Eighteen patients received chemotherapy. None of the patients received hormonal therapy. Results: Median follow-up was 72 months (95%CI: 55-not reached). Five-year local control (LC), overall survival (OS), cancer-specific survival, disease-free survival, and metastases-free rates were 47%, 53%, 56%, 35%, and 35%, respectively. Notably, curative RT (neoadjuvant, adjuvant, or definitive) was associated with improved 5-year LC (55% vs. 31%, P = 0.02) and OS (59% vs. 46%, P = 0.1). Surgically treated patients presenting with a cT3-4 tumor (n = 31), who received RT (n = 24), had a significantly improved 5-year LC (68% vs, 33%, P = 0.004) and OS (65% vs. 21%, P < 0.001) rates compared to patients not receiving RT. cT4 patients demonstrated a significantly lower 5-year OS (43% vs. 61%, P = 0.006) and LC (29% vs. 69%, P < 0.001) rates. Histologic subtype was not associated with LC and OS, but patients with prostatic stromal sarcoma, rhabdomyosarcoma, or sarcomatoid carcinoma had worse 5-year LC compared to other types (47% vs. 55%) and OS (49% vs. 58%). Conclusion: Adult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS.

AB - Introduction: Adult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients. Materials and Methods: This study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22-87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40). Curative radiotherapy (RT) was delivered in 32 patients, as radical (n = 5), neoadjuvant (n = 10), or postoperative treatment (n = 17). Eighteen patients received chemotherapy. None of the patients received hormonal therapy. Results: Median follow-up was 72 months (95%CI: 55-not reached). Five-year local control (LC), overall survival (OS), cancer-specific survival, disease-free survival, and metastases-free rates were 47%, 53%, 56%, 35%, and 35%, respectively. Notably, curative RT (neoadjuvant, adjuvant, or definitive) was associated with improved 5-year LC (55% vs. 31%, P = 0.02) and OS (59% vs. 46%, P = 0.1). Surgically treated patients presenting with a cT3-4 tumor (n = 31), who received RT (n = 24), had a significantly improved 5-year LC (68% vs, 33%, P = 0.004) and OS (65% vs. 21%, P < 0.001) rates compared to patients not receiving RT. cT4 patients demonstrated a significantly lower 5-year OS (43% vs. 61%, P = 0.006) and LC (29% vs. 69%, P < 0.001) rates. Histologic subtype was not associated with LC and OS, but patients with prostatic stromal sarcoma, rhabdomyosarcoma, or sarcomatoid carcinoma had worse 5-year LC compared to other types (47% vs. 55%) and OS (49% vs. 58%). Conclusion: Adult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS.

UR - http://www.scopus.com/inward/record.url?scp=85020303597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020303597&partnerID=8YFLogxK

U2 - 10.1002/pros.23375

DO - 10.1002/pros.23375

M3 - Article

C2 - 28594087

AN - SCOPUS:85020303597

VL - 77

SP - 1160

EP - 1166

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 10

ER -

De Bari B, Stish B, Ball MW, Habboush Y, Sargos P, Krengli M et al. Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate. 2017 Jul 1;77(10):1160-1166. https://doi.org/10.1002/pros.23375